|
| NB: The information displayed below does not replace the protocol. The latest protocol version should always be consulted before making clinical decisions. |
|
START
|
|
Standardisation of Breast Radiotherapy (START) Trial
|
|
|
Topic
|
|
Cancer
|
|
Portfolio Eligibility
|
|
Funded by UKCRC partner
|
|
|
ISRCTN
|
59368779
|
|
EudraCT
|
|
|
MREC N° |
MREC 98/96
|
|
UKCRN ID |
629
|
|
WHO ID
|
|
|
|
Research Summary
|
To test the effects of radiotherapy schedules using fraction sizes larger than 2.0 Gy in terms of normal tissue responses, loco-regional tumour control, quality of life and economic consequences in women prescribed postoperative radiotherapy for early breast cancer.
|
|
|
Study Type |
Interventional
|
|
Design Type |
Treatment
|
|
Disease(s) |
Breast
|
|
Phase |
N/A
|
|
|
Current Status
| Closed - in follow-up |
| Closure Date | 25/10/2002 |
|
Sample Size
| 4000 |
| Accrual to Date |
 | 111% |
|
|
|
Geographical Scope
| UK Multi-Centre |
|
Lead Country
| Unknown (also active in England) |
|
|
Main Inclusion Criteria
|
|
Age 18 yr. or over
Operable unilateral breast cancer (T1-3, N0-1, M0 at presentation)
Histological confirmation of invasive carcinoma
Complete macroscopic excision of tumour by breast conserving or mastectomy (ideally no microscopic evidence of invasive or in situ cancer at, or within 1mm, a resection margin)
Patient consents to be part of the study and is available for follow-up
No immediate breast reconstruction
Ineligibility :
patients requiring axillary radiotherapy after greater than a Level 1 axillary dissection or after >10 lymph nodes have been removed
|
|
|
Main Exclusion Criteria
|
|
not specified
|
|
|
Chief Investigator(s)
|
| Prof John Yarnold |
|
|
Further details, please contact
|
Mr Mark Sydenham
Institute of Cancer Research
Section of Clinical Trials
15 Cotswold Road
Sutton
SM2 5NG
UNITED KINGDOM
Tel: 0208 722 4104
Mark.Sydenham@icr.ac.uk
|
|
|
Funder(s) |
Medical Research Council
NIHR - Health Technology Assessment Programme (HTA)
Cancer Research UK
|
|
Sponsor(s) |
Institute of Cancer Research
|
|
|
|